The number of people with HIV (PWH) aged 50 years or older continues to steadily increase. The convergence of age- and HIV-related complications in these individuals presents a challenge for both patients and clinicians alike. New findings continue to emerge, as numerous researchers evaluate the combined impact of these two factors on quality of life, physiological systems, and mental health in PWH. Since its first occurrence in 2009, the International Workshop on HIV and Aging has served as a multidisciplinary meeting to share basic biomedical data, clinical trial results, treatment strategies, and epidemiological recommendations, toward better understanding and outcomes among like-minded scientific professionals. In this article, we share a selection of key findings presented in plenary talks at the 11th Annual International Workshop on HIV and Aging, held virtually from September 30, 2020 to October 2, 2020. We will also address the future directions of HIV and aging research, to further assess how the aging process intersects with chronic HIV.
Get full access to this article
View all access options for this article.
References
1.
KohliR, KleinRS, SchoenbaumEE, AnastosK, MinkoffH, SacksHS: Aging and HIV infection. J Urban Health, 2006; 83:31–42.
2.
AliskyJM: The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses, 2007; 69:1140–1143.
3.
AncesBM, EllisRJ: Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol, 2007; 27:86–92.
4.
AncesBM, OrtegaM, VaidaF, HeapsJ, PaulR: Independent effects of HIV, Aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr, 2012; 59:469–477.
5.
AncesBM, VaidaF, YehMJ, et al.: HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis, 2010; 201:336–340.
6.
BhatiaR, RyscavageP, TaiwoB: Accelerated aging and human immunodeficiency virus infection: Emerging challenges of growing older in the era of successful antiretroviral therapy. J Neurovirol, 2011; 18:247–255.
7.
DesaiS, LandayA: Early immune senescence in HIV disease. Curr HIV/AIDS Rep, 2010; 7:4–10.
8.
LevineAJ, QuachA, MooreDJ, et al.: Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. J Neurovirol, 2016; 22:366–375.
9.
StoffDM, GoodkinK, JesteD, MarquineM: Redefining aging in HIV infection using phenotypes. Curr HIV/AIDS Rep, 2017; 14:184–199.
10.
DeeksSG: Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med, 2009; 17:118–123.
11.
DeeksSG: HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med, 2011; 62:141–155.
12.
McMurtrayA, NakamotoB, ShikumaC, ValcourV: Small-vessel vascular disease in human immunodeficiency virus infection: The Hawaii aging with HIV cohort study. Cerebrovasc Dis, 2007; 24:236–241.
13.
Güerri-FernándezR, Villar-GarcíaJ, Díez-PérezA, Prieto-AlhambraD: HIV infection, bone metabolism, and fractures. Arq Bras Endocrinol Metabol, 2014; 58:478–483.
14.
ErlandsonKM, AllshouseAA, JankowskiCM, MaWhinneyS, KohrtWM, CampbellTB: Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr, 2013; 63:209–215.
15.
BouwmanFH, SkolaskyRL, HesD, et al.: Variable progression of HIV-associated dementia. Neurology, 1998; 50:1814–1820.
16.
ColeJH, UnderwoodJ, CaanMW, et al.: Increased brain-predicted aging in treated HIV disease. Neurology, 2017; 88:1349–1357.
17.
DingY, LinH, ShenW, WuQ, GaoM, HeN: Interaction effects between HIV and aging on selective neurocognitive impairment. J Neuroimmune Pharmacol, 2017; 12:661–669.
18.
PfefferbaumA, RogosaDA, RosenbloomMJ, et al.: Accelerated aging of selective brain structures in human immunodeficiency virus infection: A controlled, longitudinal magnetic resonance imaging study. Neurobiol Aging, 2014; 35:1755–1768.
19.
SheppardDP, IudicelloJE, MorganEE, et al.: Accelerated and accentuated neurocognitive aging in HIV infection. J Neurovirol, 2017; 23:492–500.
20.
CheruLT, ParkEA, SaylorCF, et al.: I-FABP is higher in people with chronic HIV than elite controllers, related to sugar and fatty acid intake and inversely related to body fat in people with HIV. Open Forum Infect Dis, 2018; 5:ofy288.
21.
ErlandsonKM, ReynoldsSM, CoxC, et al.: Self-reported body fat change in HIV-infected men is a marker of decline in physical health-related quality of life with aging, independent of co-morbidity. PLoS One, 2014; 9:e114166.
22.
GuaraldiG, LonardoA, MaiaL, PalellaFJJr.: Metabolic concerns in aging HIV-infected persons: From serum lipid phenotype to fatty liver. AIDS, 2017; 31(Suppl 2):S147–S156.
23.
MartinGE, GouillouM, HearpsAC, et al.: Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One, 2013; 8:e55279.
24.
SeiderTR, GongvatanaA, WoodsAJ, et al.: Age exacerbates HIV-associated white matter abnormalities. J Neurovirol, 2016; 22:201–212.
25.
FoleyJM, EttenhoferML, KimMS, BehdinN, CastellonSA, HinkinCH: Cognitive reserve as a protective factor in older HIV-positive patients at risk for cognitive decline. Appl Neuropsychol Adult, 2012; 19:16–25.
26.
HinesLJ, MillerEN, HinkinCH, et al.: Cortical brain atrophy and intra-individual variability in neuropsychological test performance in HIV disease. Brain Imaging Behav, 2016; 10:640–651.
27.
SchoenJC, ErlandsonKM, AndersonPL: Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol, 2013; 9:573–588.
28.
MangoniAA, JacksonSH: Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol, 2004; 57:6–14.
29.
BackD, MarzoliniC: The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc, 2020; 23:e25449.
30.
MannSC, Castillo-MancillaJR: HIV, aging, and adherence: An update and future directions. Curr Opin HIV AIDS, 2020; 15:134–141.
31.
GallantJ, HsuePY, ShreayS, MeyerN: Comorbidities among US patients with prevalent HIV infection—A trend analysis. J Infect Dis, 2017; 216:1525–1533.
32.
SánchezA, CabreraS, SantosD, et al.: Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother, 2011; 55:5314–5324.
33.
Arab-AlameddineM, Di IulioJ, BuclinT, et al.: Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther, 2009; 85:485–494.
34.
DaillyE, BillaudE, ReliquetV, et al.: No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol, 2004; 60:343–348.
35.
DickinsonL, JacksonA, GarveyL, et al.: Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients. J Int AIDS Soc, 2010; 13(Suppl 4):P184.
36.
PanhardX, LegrandM, TaburetA-M, et al.: Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol, 2007; 63:1019–1029.
37.
BenaboudS, HirtD, LaunayO, et al.: Pregnancy-related effects on tenofovir pharmacokinetics: A population study with 186 women. Antimicrob Agents Chemother, 2012; 56:857–862.
38.
ElliotER, WangX, SinghS, et al.: Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis, 2019; 68:87–95.
39.
SiccardiM, D'AvolioA, Rodriguez-NovoaS, et al.: Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit, 2012; 34:232–235.
40.
CustodioJM, GordiT, ZhongL, LingKHJ, RamanathanS: Population pharmacokinetics of boosted-elvitegravir in HIV-infected patients. J Clin Pharmacol, 2016; 56:723–732.
41.
SeifertSM, Castillo-MancillaJR, ErlandsonK, et al.: Adherence biomarker measurements in older and younger HIV-infected adults receiving tenofovir-based therapy. J Acquir Immune Defic Syndr, 2018; 77:295–298.
42.
DumondJB, BayCP, NelsonJAE, et al.: Intracellular tenofovir and emtricitabine concentrations in younger and older women with HIV receiving tenofovir disoproxil fumarate/emtricitabine. Antimicrob Agents Chemother, 2020; 64:e00177-20.
43.
BurgerD, Van Der HeidenI, La PorteC, et al.: Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: The effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol, 2006; 61:148–154.
44.
StohrW, BackD, DunnD, et al.: Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir Ther, 2008; 13:675–685.
45.
MoltóJ, XinarianosG, MirandaC, et al.: Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet, 2013; 52:543–553.
46.
KileDA, MaWhinneyS, AquilanteCL, RowerJE, Castillo-MancillaJR, AndersonPL: A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses, 2012; 28:1227–1234.
47.
LubomirovR, di IulioJ, FayetA, et al.: ADME pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics, 2010; 20:217–230.
48.
NachegaJB, HsuAJ, UthmanOA, SpinewineA, PhamPA: Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population. AIDS, 2012; 26:S39–S53.
49.
SoomroN, FitzgeraldG, SeeleyJ, SchatzE, NachegaJB, NeginJ: Comparison of antiretroviral therapy adherence among HIV-infected older adults with younger adults in Africa: Systematic review and meta-analysis. AIDS Behav, 2019; 23:445–458.
50.
GhideiL, SimoneMJ, SalowMJ, et al.: Aging, antiretrovirals, and adherence: A meta analysis of adherence among older HIV-infected individuals. Drugs Aging, 2013; 30:809–819.
51.
HinkinCH, HardyDJ, MasonKI, et al.: Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS, 2004; 18(Suppl 1):S19.
52.
AbaraWE, AdekeyeOA, XuJ, HeimanHJ, RustG: Correlates of combination antiretroviral adherence among recently diagnosed older HIV-infected adults between 50 and 64 years. AIDS Behav, 2016; 20:2674–2681.
53.
SiefriedKJ, MaoL, CysiqueLA, et al.: Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS, 2018; 32:35.
54.
EdelmanEJ, RentschCT, JusticeAC: Polypharmacy in HIV: Recent insights and future directions. Curr Opin HIV AIDS, 2020; 15:126–133.
55.
CaballeroJ, OwnbyRL, JacobsRJ, ThomasJE, SchweizerMS: Association between cognitive tests and antiretroviral medication adherence in older adults with HIV. Ann Pharmacother, 2019; 53:151–158.
56.
ViswanathanS, DetelsR, MehtaSH, MacatangayBJ, KirkGD, JacobsonLP: Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav, 2015; 19:601–611.
57.
ViswanathanS, JusticeAC, AlexanderGC, et al.: Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2015; 69:493–498.
58.
KobinAB, ShethNU: Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother, 2011; 45:372–379.
59.
ByrdKK, HouJG, HazenR, et al.: Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr, 2019; 82:245–251.
60.
Castillo-MancillaJR, BrownTT, ErlandsonKM, et al.: Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis, 2016; 63:1661–1667.
61.
Castillo-MancillaJR, PhillipsAN, NeatonJD, et al.: Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals enrolled in the SMART study. Paper presented at: Open Forum Infectious Diseases 2018; San Francisco, CA.
62.
Castillo-MancillaJR, MorrowM, BoumY, et al.: Brief report: Higher ART adherence is associated with lower systemic inflammation in treatment-naive Ugandans who achieve virologic suppression. J Acquir Immune Defic Syndr, 2018; 77:507–513.
63.
MusinguziN, Castillo-MancillaJ, MorrowM, et al.: Antiretroviral therapy adherence interruptions are associated with systemic inflammation among Ugandans who achieved viral suppression. J Acquir Immune Defic Syndr, 2019; 82:386–391.
64.
Castillo-MancillaJR, PhillipsAN, NeatonJD, et al.: Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. J Int AIDS Soc, 2019; 22:e25297.
65.
Castillo-MancillaJR, BrownTT, Palella JrFJ, et al.: Partial normalization of biomarkers of inflammation and immune activation among virally suppressed men with HIV infection and high ART adherence. Paper presented at: Open Forum Infectious Diseases, 2020; Virtual.
66.
WatersL, AhmedN, AngusB, et al.: BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). BHIVA (British HIV Association), London, 2016.
67.
SaagMS, BensonCA, GandhiRT, et al.: Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the International Antiviral Society–USA Panel. JAMA, 2018; 320:379–396.
68.
World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. World Health Organization, Geneva, 2019 (WHO/CDS/HIV/19.15).
69.
LagathuC, BéréziatV, GorwoodJ, et al.: Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf, 2019; 18:829–840.
70.
van WijkJP, CabezasMC: Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: Effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med, 2012; 2012:201027.
71.
AgarwalN, IyerD, PatelSG, et al.: HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation. Sci Transl Med, 2013; 5:213ra164.
72.
KannistoK, SutinenJ, KorsheninnikovaE, et al.: Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS, 2003; 17:1753–1762.
73.
AgarwalN, BalasubramanyamA: Viral mechanisms of adipose dysfunction: Lessons from HIV-1 Vpr. Adipocyte, 2015; 4:55–59.
74.
TiliscanC, AramaV, MihailescuR, et al.: Association of adiponectin/leptin ratio with carbohydrate and lipid metabolism parameters in HIV-infected patients during antiretroviral therapy. Endocr Res, 2018; 43:149–154.
75.
BeraldoRA, SantosAPD, GuimarãesMP, et al.: Body fat redistribution and changes in lipid and glucose metabolism in people living with HIV/AIDS. Rev Bras Epidemiol, 2017; 20:526–536.
76.
SrinivasaS, FitchKV, WongK, et al.: RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab, 2015; 100:2873–2882.
77.
BoccaraF, AuclairM, CohenA, et al.: HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther, 2010; 15:363–375.
78.
CouturierJ, WinchesterLC, SuliburkJW, et al.: Adipocytes impair efficacy of antiretroviral therapy. Antiviral Res, 2018; 154:140–148.
79.
McDermottAY, ShevitzA, KnoxT, RoubenoffR, KehayiasJ, GorbachS: Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr, 2001; 74:679–686.
80.
MaiaBS, EngelsonES, WangJ, KotlerDP: Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications for clinical nutrition. Clin Nutr, 2005; 24:971–978.
81.
ScherzerR, HeymsfieldSB, LeeD, et al.: Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS, 2011; 25:1405–1414.
82.
CroxfordS, KitchingA, DesaiS, et al.: Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: An analysis of a national observational cohort. Lancet Public Health, 2017; 2:e35–e46.
83.
WeberR, SabinCA, Friis-MøllerN, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med, 2006; 166:1632–1641.
84.
ChalasaniN, YounossiZ, LavineJE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012; 142:1592–1609.
85.
RatziuV, BellentaniS, Cortez-PintoH, DayC, MarchesiniG: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol, 2010; 53:372–384.
86.
PerazzoH, LuzPM: Liver disease and healthy life-expectancy with HIV. Lancet HIV, 2017; 4:e236–e237.
87.
Centers for Disease Control and Prevention: HIV and older Americans. 2020; https://www.cdc.gov/hiv/group/age/olderamericans/index.html.
88.
PembrokeT, DeschenesM, LebouchéB, et al.: Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol, 2017; 67:801–808.
89.
MilicJ, MenozziV, SchepisF, et al.: Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS, 2020; 34:1915–1921.
90.
KrahnT, MartelM, Sapir-PichhadzeR, et al.: Nonalcoholic fatty liver disease and the development of metabolic comorbid conditions in patients with human immunodeficiency virus infection. J Infect Dis, 2020; 222:787–797.
91.
MohrR, BoeseckeC, DoldL, et al.: Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine (Baltimore), 2018; 97:e0462.
92.
PerazzoH, CardosoSW, YanavichC, et al.: Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc, 2018; 21:e25201.
93.
PriceJC, MaY, ScherzerR, et al.: Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology, 2017; 65:853–863.
94.
GuaraldiG, SquillaceN, StentarelliC, et al.: Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: Prevalence, characteristics, and predictors. Clin Infect Dis, 2008; 47:250–257.
95.
LombardiR, SambatakouH, MariolisI, CokkinosD, PapatheodoridisGV, TsochatzisEA: Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis, 2016; 48:1471–1477.
96.
PromratK, KleinerDE, NiemeierHM, et al.: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010; 51:121–129.
97.
SebastianiG, SaeedS, LeboucheB, et al.: Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. AIDS, 2020; 34:237–244.
98.
StanleyTL, FourmanLT, FeldpauschMN, et al.: Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: A randomised, double-blind, multicentre trial. Lancet HIV, 2019; 6:e821–e830.
99.
MacíasJ, ManceboM, MerinoD, et al.: Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease. Clin Infect Dis, 2017; 65:1012–1019.
100.
BourgiK, JenkinsCA, RebeiroPF, et al.: Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc, 2020; 23:e25484.
101.
RyomL, CotterA, De MiguelR, et al.: 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med, 2020; 21:617–624.
102.
GrantPM, KitchD, McComseyGA, et al.: Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. J Infect Dis, 2016; 214:607–611.
103.
ErlandsonKM, LakeJE, SimM, et al.: Bone mineral density declines twice as quickly among HIV-infected women compared with men. J Acquir Immune Defic Syndr, 2018; 77:288–294.
104.
CazanaveC, DuponM, Lavignolle-AurillacV, et al.: Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors. AIDS, 2008; 22:395–402.
105.
HoyJF, GrundB, RoedigerM, et al.: Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: Findings from the START bone mineral density substudy, a randomized trial. J Bone Miner Res, 2017; 32:1945–1955.
106.
ShiauS, YinMT, StrehlauR, et al.: Deficits in bone architecture and strength in children living with HIV on antiretroviral therapy. J Acquir Immune Defic Syndr, 2020; 84:101–106.
107.
CarmoFB, TerreriMT, SucciRCM, et al.: Bone mineral density and vitamin D concentration: The challenges in taking care of children and adolescents infected with HIV. Braz J Infect Dis, 2017; 21:270–275.
108.
MayerKH, MolinaJM, ThompsonMA, et al.: Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): Primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet, 2020; 396:239–254.
109.
SaxPE, WohlD, YinMT, et al.: Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet, 2015; 385:2606–2615.
110.
BernardinoJI, MocroftA, MallonPW, et al.: Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV, 2015; 2:e464–e473.
111.
CosmanF, de BeurSJ, LeBoffMS, et al.: Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int, 2014; 25:2359–2381.
112.
StephensKI, RubinsztainL, PayanJ, RentschC, RimlandD, TangprichaV: Dual-energy X-ray absorptiometry and calculated FRAX risk scores may underestimate osteoporotic fracture risk in vitamin D-deficient veterans with HIV infection. Endocr Pract, 2016; 22:440–446.
113.
van WelzenBJ, YesilayS, ArendsJE, HoepelmanAIM, MudrikovaT: Brief report: Low sensitivity of the fracture risk assessment tool in young HIV-infected patients: Time to revise our screening strategy. J Acquir Immune Defic Syndr, 2019; 82:439–442.
114.
TanDH, RaboudJ, SzadkowskiL, et al.: Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: A pilot study. HIV Clin Trials, 2017; 18:28–38.
115.
BorderiM, CalzaL, ColangeliV, et al.: Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol, 2014; 37:25–32.
116.
Borges ÁH, HoyJ, FlorenceE, et al.: Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis, 2017; 64:1413–1421.
117.
HirakawaH, GatanagaH, OchiH, et al.: Antiretroviral therapy containing HIV protease inhibitors enhances fracture risk by impairing osteoblast differentiation and bone quality. J Infect Dis, 2017; 215:1893–1897.
118.
LimaAL, de OliveiraPR, PlaplerPG, et al.: Osteopenia and osteoporosis in people living with HIV: Multiprofessional approach. HIV AIDS (Auckl), 2011; 3:117–124.
119.
JhaS, WangZ, LaucisN, BhattacharyyaT: Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: An ecological analysis. J Bone Miner Res, 2015; 30:2179–2187.
120.
Diker-CohenT, RosenbergD, AvniT, ShepshelovichD, TsvetovG, Gafter-GviliA: Risk for infections during treatment with denosumab for osteoporosis: A systematic review and meta-analysis. J Clin Endocrinol Metab, 2020; 105:1641–1658.
121.
JackCRJr., KnopmanDS, JagustWJ, et al.: Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol, 2013; 12:207–216.
122.
HajishengallisG: Immunomicrobial pathogenesis of periodontitis: Keystones, pathobionts, and host response. Trends Immunol, 2014; 35:3–11.
123.
HajishengallisG: The inflammophilic character of the periodontitis-associated microbiota. Mol Oral Microbiol, 2014; 29:248–257.
124.
EkePI, DyeBA, WeiL, et al.: Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. J Periodontol, 2015; 86:611–622.
125.
HajishengallisG, LamontRJ: Dancing with the stars: How choreographed bacterial interactions dictate nososymbiocity and give rise to keystone pathogens, accessory pathogens, and pathobionts. Trends Microbiol, 2016; 24:477–489.
126.
KamerAR, CraigRG, DasanayakeAP, BrysM, Glodzik-SobanskaL, de LeonMJ: Inflammation and Alzheimer's disease: Possible role of periodontal diseases. Alzheimers Dement, 2008; 4:242–250.
127.
OffenbacherS, JiaoY, KimSJ, et al.: GWAS for interleukin-1beta levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun, 2018; 9:3686.
128.
ParaskevasS, HuizingaJD, LoosBG: A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol, 2008; 35:277–290.
129.
SocranskySS, HaffajeeAD: The nature of periodontal diseases. Ann Periodontol, 1997; 2:3–10.
130.
HaffajeeAD, SocranskySS: Introduction to microbial aspects of periodontal biofilm communities, development and treatment. Periodontol 2000, 2006; 42:7–12.
131.
KumarPS, GriffenAL, BartonJA, PasterBJ, MoeschbergerML, LeysEJ: New bacterial species associated with chronic periodontitis. J Dent Res, 2003; 82:338–344.
132.
KumarPS, GriffenAL, MoeschbergerML, LeysEJ: Identification of candidate periodontal pathogens and beneficial species by quantitative 16S clonal analysis. J Clin Microbiol, 2005; 43:3944–3955.
133.
GriffenAL, BeallCJ, CampbellJH, et al.: Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. ISME J, 2012; 6:1176–1185.
134.
KrishnanK, ChenT, PasterBJ: A practical guide to the oral microbiome and its relation to health and disease. Oral Dis, 2017; 23:276–286.
135.
KamerAR, CraigRG, NiedermanR, ForteaJ, de LeonMJ: Periodontal disease as a possible cause for Alzheimer's disease. Periodontol 2000, 2020; 83:242–271.
136.
KamerAR, PirragliaE, TsuiW, et al.: Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiol Aging, 2015; 36:627–633.
137.
DominySS, LynchC, ErminiF, et al.: Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv, 2019; 5:eaau3333.
138.
IlievskiV, ZuchowskaPK, GreenSJ, et al.: Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One, 2018; 13:e0204941.
139.
FriedmanDS, O'ColmainBJ, MuñozB, et al.: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol, 2004; 122:564–572.
140.
ZhouM, DuanPC, LiangJH, ZhangXF, PanCW: Geographic distributions of age-related macular degeneration incidence: a systematic review and meta-analysis. Br J Ophthalmol, 2020; [Epub ahead of print]; DOI: 10.1136/bjophthalmol-2020-316820.
141.
FerrisFL, 3rd, WilkinsonCP, BirdA, et al.: Clinical classification of age-related macular degeneration. Ophthalmology, 2013; 120:844–851.
142.
SchifittoG, McDermottMP, McArthurJC, et al.: Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology, 2002; 58:1764–1768.
143.
LetendreS, EllisRJ: Neurologic complications of HIV disease and their treatments. Top HIV Med, 2006; 14:21–26.
144.
EllisRJ, DiazM, SacktorN, et al.: Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Ann Clin Transl Neurol, 2020; 7:1166–1173.
145.
HalloranMO, BoyleC, KehoeB, et al.: Polypharmacy and drug-drug interactions in older and younger people living with HIV: The POPPY study. Antivir Ther, 2019; 24:193–201.
146.
VerheggenICM, de JongJJA, van BoxtelMPJ, et al.: Increase in blood-brain barrier leakage in healthy, older adults. Geroscience, 2020; 42:1183–1193.
147.
MazzitelliM, MilinkovicA, PereiraB, et al.: Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV. AIDS, 2019; 33:2439–2441.
148.
PetoumenosK, ReissP, RyomL, et al.: Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med, 2014; 15:595–603.
149.
PereiraB, MazzitelliM, MilinkovicA, et al.: Use of coronary artery calcium scoring to improve cardiovascular risk stratification and guide decisions to start statin therapy in people living with HIV. J Acquir Immune Defic Syndr, 2020; 85:98–105.
150.
GuaraldiG, CossarizzaA: Geriatric-HIV medicine: A science in its infancy. Virulence, 2017; 8:504–507.
151.
ChangL, AndresM, SadinoJ, et al.: Impact of apolipoprotein E epsilon4 and HIV on cognition and brain atrophy: Antagonistic pleiotropy and premature brain aging. Neuroimage, 2011; 58:1017–1027.
152.
MorganEE, IudicelloJE, WeberE, et al.: Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr, 2012; 61:341–348.
153.
KisselEC, Pukay-MartinND, BornsteinRA: The relationship between age and cognitive function in HIV-infected men. J Neuropsychiatry Clin Neurosci, 2005; 17:180–184.
154.
ThomasJB, BrierMR, SnyderAZ, VaidaFF, AncesBM: Pathways to neurodegeneration: Effects of HIV and aging on resting-state functional connectivity. Neurology, 2013; 80:1186–1193.
155.
ValcourV, PaulR, NeuhausJ, ShikumaC: The effects of age and HIV on neuropsychological performance. J Int Neuropsychol Soc, 2011; 17:190–195.
